Arvinas (NASDAQ:ARVN) Insider Noah Berkowitz Sells 11,108 Shares of Stock

Arvinas, Inc. (NASDAQ:ARVN) insider Noah Berkowitz sold 11,108 shares of the company’s stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $9.94, for a total value of $110,413.52. Following the completion of the sale, the insider owned 191,395 shares of the company’s stock, valued at $1,902,466.30. This trade represents a 5.49% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Noah Berkowitz also recently made the following trade(s):

• On Wednesday, March 18th, Noah Berkowitz sold 6,435 shares of Arvinas stock. The stock was sold at an average price of $11.10, for a total value of $71,428.50.
• On Friday, February 13th, Noah Berkowitz sold 5,685 shares of Arvinas stock. The stock was sold at an average price of $11.89, for a total value of $67,594.65.

Arvinas Trading Up 3.1%

Shares of NASDAQ ARVN opened at $9.87 on Thursday. The stock has a market cap of $636.81 million, a P/E ratio of -2.97 and a beta of 1.79. Arvinas, Inc. has a 12-month low of $5.90 and a 12-month high of $14.51. The business’s fifty day simple moving average is $11.14 and its 200-day simple moving average is $11.69.

Arvinas (NASDAQ:ARVN) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.90) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.95) by $0.05. Arvinas had a negative return on equity of 44.38% and a negative net margin of 247.54%.The company had revenue of $15.60 million for the quarter, compared to analysts’ expectations of $16.61 million. During the same period last year, the firm earned $1.14 earnings per share. Arvinas’s quarterly revenue was down 91.7% on a year-over-year basis. On average, equities analysts forecast that Arvinas, Inc. will post -3.29 EPS for the current fiscal year.

Key Arvinas News

Here are the key news stories impacting Arvinas this week:

• Positive Sentiment: BTIG Research raised its price target on Arvinas to $18.00 from $16.00 and reiterated a Buy rating, signaling confidence in meaningful upside from current levels. Arvinas (NASDAQ:ARVN) Price Target Raised to $18.00 at BTIG Research
• Positive Sentiment: Arvinas and Pfizer’s breast cancer drug VEPPANU (vepdegestrant) was licensed to Rigel Pharmaceuticals, with the deal including $85 million upfront plus up to $320 million in milestones. That provides validation for Arvinas’ PROTAC platform and adds potential future non-dilutive funding. Rigel strikes licensing deal for Pfizer and Arvinas’ breast cancer drug
• Neutral Sentiment: Arvinas reported Q1 earnings of -$0.90 per share, slightly better than estimates, but revenue of $15.6 million missed expectations and fell sharply from last year, underscoring that profitability is still distant. Arvinas, Inc. (ARVN) Reports Q1 Loss, Misses Revenue Estimates
• Negative Sentiment: CEO Randy Teel, CFO Andrew Saik, CAO David K. Loomis, and insider Noah Berkowitz all sold shares, though the filings indicate the sales were mainly for tax withholding tied to equity vesting. While routine, insider sales can still weigh on sentiment. CEO insider filing

Analyst Ratings Changes

A number of brokerages have weighed in on ARVN. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Arvinas in a report on Friday, April 10th. Citigroup lifted their price objective on Arvinas from $21.00 to $24.00 and gave the stock a “buy” rating in a research report on Monday, May 4th. BTIG Research boosted their price target on Arvinas from $16.00 to $18.00 and gave the company a “buy” rating in a report on Wednesday. Barclays boosted their price target on Arvinas from $18.00 to $20.00 and gave the company an “overweight” rating in a report on Wednesday. Finally, Piper Sandler reissued an “overweight” rating and set a $20.00 price objective (up from $16.00) on shares of Arvinas in a research note on Wednesday, February 25th. Nine investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $15.14.

Institutional Trading of Arvinas

Institutional investors have recently added to or reduced their stakes in the business. Tower Research Capital LLC TRC boosted its position in Arvinas by 491.4% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,819 shares of the company’s stock worth $43,000 after purchasing an additional 4,835 shares during the period. Canada Pension Plan Investment Board boosted its position in Arvinas by 109.4% in the 2nd quarter. Canada Pension Plan Investment Board now owns 6,700 shares of the company’s stock valued at $49,000 after buying an additional 3,500 shares during the last quarter. State of Wyoming purchased a new position in Arvinas in the 3rd quarter valued at about $68,000. Aster Capital Management DIFC Ltd purchased a new position in Arvinas in the 3rd quarter valued at about $92,000. Finally, Jain Global LLC purchased a new position in Arvinas in the 3rd quarter valued at about $95,000. 95.19% of the stock is owned by hedge funds and other institutional investors.

About Arvinas

Arvinas, Inc (NASDAQ: ARVN) is a biopharmaceutical company focused on the development of therapies based on targeted protein degradation. Utilizing its proprietary proteolysis-targeting chimera (PROTAC®) platform, Arvinas aims to selectively eliminate disease-causing proteins rather than merely inhibit their activity. This novel approach has the potential to address a range of diseases, including oncology, neurodegeneration and inflammation, by harnessing the body’s natural protein-recycling systems.

The company’s most advanced clinical candidates address hormone-driven cancers.